###begin article-title 0
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon
###end article-title 0
###begin p 1
###xml 0 14 0 14 <sc xmlns:xlink="http://www.w3.org/1999/xlink">ANGELO A. IZZO</sc>
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sc>ANGELO A. IZZO</sc></bold>
###xml 487 487 483 483 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_248_Figa_HTML" id="MO1"/>
ANGELO A. IZZO was graduated in Pharmaceutical Chemistry in 1991 and received his Ph.D. in 1995 in Pharmaceutical Sciences at the University of Naples Federico II. He is presently an Associate Professor at the School of Pharmacy (University of Naples Federico II). His research interests include the study of the receptors for plant-derived compounds (e.g., cannabinoid, vanilloid, and kappa-opioid receptors) and their role in the physiology and pathophysiology of the digestive tract. 
###end p 1
###begin p 2
###xml 0 17 0 17 <sc xmlns:xlink="http://www.w3.org/1999/xlink">VINCENZO DI MARZO</sc>
###xml 0 17 0 17 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sc>VINCENZO DI MARZO</sc></bold>
###xml 505 505 505 505 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_248_Figb_HTML" id="MO2"/>
VINCENZO DI MARZO received a degree in Chemistry of the University of Naples and a Ph.D. in biochemistry and molecular pharmacology at the Imperial College, London. He is Research Director at the Institute of Biomolecular Chemistry of the National Research Council in Pozzuoli, Naples, and Coordinator of the Endocannabinoid Research Group in the Naples Region. His research interests include the biosynthesis, metabolism, and physio-pathological role of endocannabinoids and bioactive fatty acid amides. 
###end p 2
###begin p 3
###xml 974 975 974 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1145 1146 1145 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1322 1323 1322 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1476 1477 1476 1477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 317 322 <span type="species:ncbi:10090">mouse</span>
###xml 1511 1515 <span type="species:ncbi:10090">mice</span>
###xml 1698 1703 <span type="species:ncbi:10090">mouse</span>
Colorectal cancer is an increasingly important cause of death in Western countries. Endocannabinoids inhibit colorectal carcinoma cell proliferation in vitro. In this paper, we investigated the involvement of endocannabinoids on the formation of aberrant crypt foci (ACF, earliest preneoplastic lesions) in the colon mouse in vivo. ACF were induced by azoxymethane (AOM); fatty acid amide hydrolase (FAAH) and cannabinoid receptor messenger ribonucleic acid (mRNA) levels were analyzed by the quantitative reverse transcription polymerase chain reaction (RT-PCR); endocannabinoid levels were measured by liquid chromatography-mass spectrometry; caspase-3 and caspase-9 expressions were measured by Western blot analysis. Colonic ACF formation after AOM administration was associated with increased levels of 2-arachidonoylglycerol (with no changes in FAAH and cannabinoid receptor mRNA levels) and reduction in cleaved caspase-3 and caspase-9 expression. The FAAH inhibitor N-arachidonoylserotonin increased colon endocannabinoid levels, reduced ACF formation, and partially normalized cleaved caspase-3 (but not caspase-9) expression. Notably, N-arachidonoylserotonin completely prevented the formation of ACF with four or more crypts, which have been show to be best correlated with final tumor incidence. The effect of N-arachidonoylserotonin on ACF formation was mimicked by the cannabinoid receptor agonist HU-210. No differences in ACF formation were observed between CB1 receptor-deficient and wild-type mice. It is concluded that pharmacological enhancement of endocannabinoid levels (through inhibition of endocannabinoid hydrolysis) reduces the development of precancerous lesions in the mouse colon. The protective effect appears to involve caspase-3 (but not caspase-9) activation.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
Colon cancer remains a leading cause of death because of cancer in the Western countries; the cumulative lifetime risk of developing colorectal cancer is approximately 5-6% [1]. Development of colon cancer is a multistep process involving a series of pathological alterations ranging from discrete microscopic mucosal lesions, like aberrant crypt foci (ACF), to malignant tumors [2]. ACF are early focal lesions of the colonic mucosa composed of one to several enlarged crypts, which are specifically induced by colon carcinogens [3]. Easily identified in methylene blue-stained whole-mount preparations under a dissecting microscope, ACF are used as early indicators of colon carcinogenesis [1-3].
###end p 6
###begin p 7
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 265 266 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 399 400 395 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 407 408 403 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 420 421 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 586 587 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 588 589 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 920 921 916 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 923 924 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
Cannabinoids have been licensed for clinical use as palliative treatment of chemotherapy, but increasing evidence shows antitumor actions of cannabinoid agonists on several tumor cells in vitro and in animal models [4, 5]. The main psychotropic cannabinoid is Delta9-tetrahydrocannabinol, which exerts its biological effects mainly by activating two G protein-coupled cannabinoid receptors, named CB1 and CB2 receptors [5]. Endogenous ligands for the cannabinoid receptors have been identified; the best known are arachidonylethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG) [4-6]. When released, anandamide and 2-AG are removed from extracellular compartments by a carrier-mediated reuptake process, and once within the cell, both endocannabinoids are hydrolyzed by intracellular hydrolytic enzymes of which the enzyme fatty acid amide hydrolase (FAAH) is capable of recognizing both compounds as substrates [5, 6].
###end p 7
###begin p 8
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 361 362 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 451 452 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 740 741 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 821 822 821 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 840 841 840 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
The proposed mechanisms of the antitumoral effect of cannabinoids are complex and may involve induction of apoptosis in tumor cells, antiproliferative actions, and an antimetastatic effects through inhibition of angiogenesis and tumor cell migration [6]. Concerning the gastrointestinal tract, it has been shown that cannabinoid receptor agonists, mostly via CB1 activation, potently inhibit the cell proliferation of colorectal carcinoma cell lines [7]. Furthermore, compounds capable of inhibiting endocannabinoid degradation and hence of prolonging the lifespan of endocannabinoids only when and where these compounds are produced to exert physiological or pathophysiological functions also inhibit colorectal carcinoma growth in vitro [7]. Finally, in a study performed on SW480 colon carcinoma cells, Joseph et al. [8] reported that CB1 activation by anandamide inhibited tumor cell migration, which is of paramount importance in metastasis development. However, the potential antitumoral effect of cannabinoids, endocannabinoids, and drugs that pharmacologically manipulate endocannabinoid levels and action in the gastrointestinal tract has never been explored in vivo.
###end p 8
###begin p 9
###xml 10 11 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 193 194 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 409 410 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 498 499 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z</italic>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 619 620 619 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 623 624 623 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 938 939 938 939 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 952 953 952 953 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1093 1094 1093 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1095 1096 1095 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1211 1212 1211 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1213 1214 1213 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1361 1362 1361 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 682 687 <span type="species:ncbi:10090">mouse</span>
Because CB1 receptor activation results in inhibition of colorectal cell proliferation in vitro [7], we investigated here the role of these receptors in the formation of ACF in vivo by using CB1 receptor-deficient mice. In addition, in pharmacological experiments, we also evaluated the effect of drugs that are known to increase endocannabinoid levels in the gastrointestinal tract (i.e., the FAAH inhibitor N-arachidonoylserotonin [AA-5-HT] and the endocannabinoid reuptake inhibitor VDM11 [(all Z) N-(2-methyl-3-hydroxy-phenyl)-5,8,11,14-eicosa-tetraenamide]), as well as the effect of the ultrapotent cannabinoid CB1/CB2 receptor agonist, HU-210, on the formation of ACF in the mouse colon in vivo. We also evaluated, by quantitative reverse transcription polymerase chain reaction (RT-PCR), the degree of expression of the messenger ribonucleic acids (mRNAs) encoding for the components of the endogenous cannabinoid system (i.e., CB1 receptor, CB2 receptor, transient receptor potential vanilloid type 1 [TRPV1], FAAH), which have been implicated in cell proliferation and/or apoptosis [4-6]. Finally, because cannabinoids might exert antitumor actions by counteracting caspase activation in tumor cells [4-6], we evaluated the expression of caspase-3 and caspase-9 by Western blot analysis. ACF were induced by the genotoxic chemical azoxymethane (AOM) [9].
###end p 9
###begin title 10
Materials and methods
###end title 10
###begin title 11
Animals
###end title 11
###begin p 12
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 365 369 <span type="species:ncbi:10090">Mice</span>
###xml 404 409 <span type="species:ncbi:10090">mouse</span>
Experiments were performed on female 5-week-old C57BL/6N mice (Harlan Italy, Corezzana, MI; 20-22 g). In some experiments, female mice lacking the CB1 receptor gene, generated and genotyped as previously described [10], were used. Mutant mice were in a mixed genetic background with a predominance of C57BL/6N contribution (five backcrosses for both mutant lines). Mice were fed ad libitum with standard mouse food, except for the 12-h period immediately preceding the killing of the animals. All experiments complied with the Italian D.L. no. 116 of 27 January 1992 and associated guidelines in the European Communities Council Directive of 24 November 1986 (86/609/ECC).
###end p 12
###begin title 13
Treatments
###end title 13
###begin p 14
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 498 499 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 500 501 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 607 608 607 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
Mice were randomly divided into six groups as follows. Group 1 was treated with vehicles; group 2 was treated with AOM plus the vehicle used to dissolve cannabinoid drugs; group 3 was treated with AOM plus the FAAH inhibitor AA-5-HT (5 mg/kg); group 4 was treated with AOM plus the anandamide transporter inhibitor VDM11 (5 mg/kg); group 5 was treated with AOM plus the cannabinoid receptor agonist HU210 ((6aR)-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; 0.1 mg/kg). In another series of experiments, AOM was given both to wild-type and to CB1 deficient mice. AOM (16 mg/kg in total, IP) was administered during the first (3 m/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at days 1 and 5) of treatment.
###end p 14
###begin p 15
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
Cannabinoid drugs were given intraperitoneally every other day for the whole duration of the experiment (starting from a week before the first injection of AOM). The doses of cannabinoids were selected on the basis of previous published work dealing with the effects of these drugs in subchronic or chronic experiments [11-13].
###end p 15
###begin p 16
###xml 51 52 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
All animals were euthanized by asphyxiation with CO2 6 months after the first injection of AOM. Based on our laboratory experience, this time (at the dose of AOM used) was associated with the occurrence of a significant number of ACF.
###end p 16
###begin title 17
Aberrant crypt foci technique
###end title 17
###begin p 18
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
For ACF determination, the colons were rapidly removed after killing, washed with saline, opened longitudinally, laid flat on a polystyrene board, and fixed with 10% buffered formaldehyde solution before being stained with 0.2% methylene blue in saline. The colons were examined using a light microscope at 40x magnification. Aberrant crypts were identified as previously described [9]. Briefly, in comparison to normal crypts, aberrant crypts have greater size, larger and often elongated openings, thicker lining of epithelial cells, compression of adjacent crypts, and are more darkly stained with methylene blue. According to the number of constituent crypt, ACF were divided into two groups: small ACF containing one to three crypts per focus and large ACF containing four or more crypts per focus. To determine crypt multiplicity, the number of aberrant crypts in each focus was recorded.
###end p 18
###begin title 19
Identification and quantification of endocannabinoids and palmitoylethanolamide
###end title 19
###begin p 20
###xml 397 398 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 398 399 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">8</sub>
###xml 412 413 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 413 414 407 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 442 443 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 443 444 437 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 519 521 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 561 562 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 562 563 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 691 693 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 962 964 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 966 968 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Full-thickness colons from control and AOM-treated mice (in the presence or absence of AA-5-HT 5 mg/kg) were removed (6 months after the first injection of AOM), and tissue specimens were immediately weighed, immersed into liquid nitrogen, and stored at -70degreesC until extraction of endocannabinoids. Tissues were extracted with chloroform/methanol (2:1, by volume) containing each 200 pmol of d8-anandamide, d4-palmitoylethanolamide, and d5-2-AG, synthesized as described previously (for the former two compounds) [14], or provided by Cayman Chemicals (for d5-2-AG, AnnArbor, MI). The lipid extracts were purified by silica column chromatography and carried out as described previously [14], and the fractions containing anandamide, palmitoylethanolamide, and 2-AG were analyzed by isotope dilution liquid chromatography-atmospheric pressure-chemical ionization mass spectrometry carried out in the selected monitoring mode as described in detail elsewhere [10, 14]. Results were expressed as picomoles or nanomoles per milligram of extracted lipids.
###end p 20
###begin title 21
Western blot analysis
###end title 21
###begin p 22
###xml 241 242 238 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 446 447 443 444 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 449 450 446 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 677 679 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 1347 1353 <span type="species:ncbi:9986">rabbit</span>
###xml 1576 1582 <span type="species:ncbi:9986">rabbit</span>
###xml 1587 1598 <span type="species:ncbi:3704">horseradish</span>
Full-thickness colons from control and AOM-treated (6 months after the first injection of AOM) mice (in the presence or absence of AA-5-HT 5 mg/kg) were homogenized in lysis buffer (1:2 w/v) containing 0.5 M beta-glycerophosphate, 20 mM MgCl2, 10 mM ethylene glycol tetraacetic acid, and supplemented with 100 mM dithiothreitol and protease/phosphatase inhibitors (100 mM dimethylsulfonyl fluoride, 2 mg/ml apronitin, 2 mM leupeptin, and 10 mM Na3VO4). Homogenates were centrifuged at 3,000 rpm for 5 min at 4degreesC; the supernatants were collected and recentrifuged at 12,000 rpm for 10 min at 4degreesC. Protein concentrations were determined using the method of Bradford [15]. For Western blot analysis, lysate aliquots containing 50 mug of proteins were denatured, separated on a 12% sodium dodecyl sulfate-polyacrylamide gel, and transferred to a nitrocellulose membrane (Amersham, Biosciences, UK) using a Bio-Rad Transblot (350 mA for 3 h). Proteins were visualized on the filters by reversible staining with Ponceau-S solution (Sigma, Milan, Italy) and destained in phosphate-buffered saline (PBS). Membranes were blocked at 4degreesC in milk buffer (5% nonfat dry milk in PBS 1x/Tween 0.1%) and then incubated overnight at 4degreesC with polyclonal antibodies for caspase-3 and caspase-9 (Calbiochem from VWR International, Italy). The rabbit polyclonal anti-caspase-3 and anti-caspase-9 were used at 1:1,000 dilution in milk buffer (5% nonfat dry milk in PBS 1x/Tween 0.1%). Subsequently, the membranes were incubated for 1 h at room temperature with 1:2,000 anti-rabbit IgG-horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences, UK). After washing with PBS 1x/Tween 0.1%, the membranes were analyzed by enhanced chemiluminescence (Amersham Biosciences). The optical density of the bands on autoradiographic films was determined by an image analysis system (GS 700 Imaging Densitometer, Bio-Rad) equipped with a software Molecular Analyst (IBM). After stripping, the membranes were probed with anti-alpha-tubulin antibody, to normalize the results.
###end p 22
###begin title 23
Quantitative (real-time) RT PCR analysis
###end title 23
###begin p 24
###xml 1047 1048 1019 1020 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1157 1160 1129 1132 <sub xmlns:xlink="http://www.w3.org/1999/xlink">260</sub>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Full-thickness colons from control and AOM-treated (6 months after the first injection of AOM) mice were homogenized in 1 ml of Trizol(R) (Invitrogen). Total RNA was extracted according to manufacturer recommendations, dissolved in RNA storage solution (Ambion), UV quantified by a Bio-Photometer(R) (Eppendorf), and stored to -80degreesC. RNA aliquots (6 mug) were digested by RNAse-free DNAse I (Ambion deoxyribonucleic acid [DNA]-freetrade mark kit) in a 20-mul final volume reaction mixture, to remove contaminating genomic DNA. After DNAse digestion, concentration and purity of RNA samples were evaluated by the RNA-6000-Nano(R) microchip assay, using a 2100 Bioanalyzer(R) equipped with a 2100-Expert-Software(R) (Agilent), following the manufacturer instructions. For all samples tested, the RNA integrity number was greater than 6 (relatively to a 0-10 scale). Three micrograms of total RNA, as evaluated by the 2100 Bioanalyzer, was reverse transcribed in a 25-mul reaction mixture containing: 50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, 1 mM deoxyribonucleotide triphosphates, 20 U of RNAse inhibitor (Invitrogen), 0.125 A260 units of hexanucleotide mixture (Invitrogen) for random priming and 200 U of MoMuLV Superscript(R) III reverse transcriptase (Invitrogen). The reaction mixture was incubated in a termocycler iCycler-iQ(R) for a 5 min at a 55degreesC step, followed by a rapid chilling for 2 min at 4degreesC. The protocol was stopped at this step and the MoMuLV reverse transcriptase was added to the samples, excepting the negative controls (-RT). The incubation was resumed by two thermal steps: 10 min at 20degreesC followed by 90 min at 50degreesC. Finally, the reaction was terminated by heating at 95degreesC for 10 min. Quantitative real-time PCR was performed by an iCycler-iQ(R) in a 25-mul reaction mixture containing: 1x iQ-SYBR(R)-Green-Supermix (Bio-Rad), 20 ng of complementary DNA (cDNA; calculated on the basis of the retro-transcribed RNA), and 330 nM for each primer. The amplification profile consisted of an initial denaturation of 2 min at 94degreesC and 40 cycles of 30 s at 94degreesC, annealing for 30 s at optimum annealing temperature (TaOpt, see below) and elongation for 45 s at 68degreesC. Fluorescence data were collected during the elongation step. A final extension of 7 min was carried out at 72degreesC, followed by melt-curve data analysis. Optimized primers for SYBR(R)-Green analysis (and relative TaOpt) were designed by the Beacon-Designer(R) software 6.0 version (Biosoft International, Palo Alto, CA) and were synthesized (high-performance liquid chromatography purification grade) by MWG-Biotech AG, Germany. Assays were performed in quadruplicate (maximum DeltaCt of replicate samples less than 0.5), and a standard curve from consecutive fivefold dilutions (100 to 0.16 ng) of a cDNA pool representative of all samples was included, for PCR efficiency determination. Relative expression analysis, correct for PCR efficiency and normalized with respect to reference genes beta-actin and glyceraldehyde-3-phosphate dehydrogenase (GADPH), was performed by GENEX software (Bio-Rad) for groupwise comparison and statistical analysis.
###end p 24
###begin title 25
Drugs
###end title 25
###begin p 26
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
AOM and HU210 were purchased from Sigma and Tocris Cookson (Bristol, UK), respectively. AA-5-HT and VDM11 were synthesized as described previously [16, 17]. All drugs (with the exception of AOM, which was dissolved in saline) were first dissolved in dimethylsulfoxide (DMSO) and then suspended in a lipophilic solution (Peceol/Gelucire 44/14, gift from Indena, Milan, Italy; 0.4% DMSO, 96.6% lipophilic solution). The drug vehicle (2.5 ml/kg) had no effect on the response under study.
###end p 26
###begin title 27
Statistics
###end title 27
###begin p 28
Data are expressed as the mean +/- SEM. To determine statistical significance, analysis of varance followed by the Dunnett's (or Bonferroni's for endocannabinoid levels) test was used.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
Aberrant crypt foci formation
###end title 30
###begin p 31
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 758 765 754 761 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 765 970 761 966 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">Effect of cannabinoid drugs (arachidonoylserotonin [AA-5-HT, 5&#160;mg/kg], VDM11 [5 mg/kg], and HU210 [0.1&#160;mg/kg]) on the formation of aberrant crypt foci (ACF) induced in the mouse colon by azoxymethane (AOM)</p>
###xml 765 970 761 966 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">Effect of cannabinoid drugs (arachidonoylserotonin [AA-5-HT, 5&#160;mg/kg], VDM11 [5 mg/kg], and HU210 [0.1&#160;mg/kg]) on the formation of aberrant crypt foci (ACF) induced in the mouse colon by azoxymethane (AOM)</p></caption>
###xml 970 997 966 993 <th xmlns:xlink="http://www.w3.org/1999/xlink">Treatment (intraperitoneal)</th>
###xml 997 1016 993 1012 <th xmlns:xlink="http://www.w3.org/1999/xlink">Number of ACF/mouse</th>
###xml 1016 1058 1012 1052 <th xmlns:xlink="http://www.w3.org/1999/xlink">Number of ACF/mouse containing &#8805;4 crypts</th>
###xml 970 1058 966 1052 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Treatment (intraperitoneal)</th><th>Number of ACF/mouse</th><th>Number of ACF/mouse containing &#8805;4 crypts</th></tr>
###xml 970 1058 966 1052 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Treatment (intraperitoneal)</th><th>Number of ACF/mouse</th><th>Number of ACF/mouse containing &#8805;4 crypts</th></tr></thead>
###xml 1058 1065 1052 1059 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 1065 1066 1059 1060 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 1066 1067 1060 1061 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 1058 1067 1052 1061 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Control</td><td>0</td><td>0</td></tr>
###xml 1067 1070 1061 1064 <td xmlns:xlink="http://www.w3.org/1999/xlink">AOM</td>
###xml 1070 1082 1064 1074 <td xmlns:xlink="http://www.w3.org/1999/xlink">12.8&#8201;&#177;&#8201;2.4</td>
###xml 1082 1095 1074 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.57&#8201;&#177;&#8201;0.20</td>
###xml 1067 1095 1061 1085 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AOM</td><td>12.8&#8201;&#177;&#8201;2.4</td><td>0.57&#8201;&#177;&#8201;0.20</td></tr>
###xml 1095 1105 1085 1095 <td xmlns:xlink="http://www.w3.org/1999/xlink">AOM+AA-5HT</td>
###xml 1105 1117 1095 1105 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.3&#8201;&#177;&#8201;1.4*</td>
###xml 1117 1119 1105 1107 <td xmlns:xlink="http://www.w3.org/1999/xlink">0*</td>
###xml 1095 1119 1085 1107 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AOM+AA-5HT</td><td>6.3&#8201;&#177;&#8201;1.4*</td><td>0*</td></tr>
###xml 1119 1128 1107 1116 <td xmlns:xlink="http://www.w3.org/1999/xlink">AOM+VDM11</td>
###xml 1128 1140 1116 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.0&#8201;&#177;&#8201;1.08</td>
###xml 1140 1153 1126 1137 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.50&#8201;&#177;&#8201;0.29</td>
###xml 1119 1153 1107 1137 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AOM+VDM11</td><td>8.0&#8201;&#177;&#8201;1.08</td><td>0.50&#8201;&#177;&#8201;0.29</td></tr>
###xml 1153 1162 1137 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink">AOM+HU210</td>
###xml 1162 1174 1146 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#8201;&#177;&#8201;1.1*</td>
###xml 1174 1176 1156 1158 <td xmlns:xlink="http://www.w3.org/1999/xlink">0*</td>
###xml 1153 1176 1137 1158 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AOM+HU210</td><td>5.1&#8201;&#177;&#8201;1.1*</td><td>0*</td></tr>
###xml 1058 1176 1052 1158 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Control</td><td>0</td><td>0</td></tr><tr><td>AOM</td><td>12.8&#8201;&#177;&#8201;2.4</td><td>0.57&#8201;&#177;&#8201;0.20</td></tr><tr><td>AOM+AA-5HT</td><td>6.3&#8201;&#177;&#8201;1.4*</td><td>0*</td></tr><tr><td>AOM+VDM11</td><td>8.0&#8201;&#177;&#8201;1.08</td><td>0.50&#8201;&#177;&#8201;0.29</td></tr><tr><td>AOM+HU210</td><td>5.1&#8201;&#177;&#8201;1.1*</td><td>0*</td></tr></tbody>
###xml 970 1176 966 1158 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Treatment (intraperitoneal)</th><th>Number of ACF/mouse</th><th>Number of ACF/mouse containing &#8805;4 crypts</th></tr></thead><tbody><tr><td>Control</td><td>0</td><td>0</td></tr><tr><td>AOM</td><td>12.8&#8201;&#177;&#8201;2.4</td><td>0.57&#8201;&#177;&#8201;0.20</td></tr><tr><td>AOM+AA-5HT</td><td>6.3&#8201;&#177;&#8201;1.4*</td><td>0*</td></tr><tr><td>AOM+VDM11</td><td>8.0&#8201;&#177;&#8201;1.08</td><td>0.50&#8201;&#177;&#8201;0.29</td></tr><tr><td>AOM+HU210</td><td>5.1&#8201;&#177;&#8201;1.1*</td><td>0*</td></tr></tbody></table>
###xml 1176 1512 1158 1494 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">AOM (16&#160;mg/kg in total, intraperitoneal) was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5). Animals were euthanized 6&#160;months after the first injection of AOM. Cannabinoid drugs were given every other day for the whole duration of the experiment.</p>
###xml 1513 1514 1495 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1530 1531 1512 1513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1512 1571 1494 1553 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">*<italic>p</italic>&#8201;&lt;&#8201;0.05 vs AOM (<italic>n</italic>&#8201;=&#8201;6&#8211;9 mice for each experimental group)</p>
###xml 1176 1571 1158 1553 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">AOM (16&#160;mg/kg in total, intraperitoneal) was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5). Animals were euthanized 6&#160;months after the first injection of AOM. Cannabinoid drugs were given every other day for the whole duration of the experiment.</p><p textid="34">*<italic>p</italic>&#8201;&lt;&#8201;0.05 vs AOM (<italic>n</italic>&#8201;=&#8201;6&#8211;9 mice for each experimental group)</p></table-wrap-foot>
###xml 758 1571 754 1553 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="32">Effect of cannabinoid drugs (arachidonoylserotonin [AA-5-HT, 5&#160;mg/kg], VDM11 [5 mg/kg], and HU210 [0.1&#160;mg/kg]) on the formation of aberrant crypt foci (ACF) induced in the mouse colon by azoxymethane (AOM)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Treatment (intraperitoneal)</th><th>Number of ACF/mouse</th><th>Number of ACF/mouse containing &#8805;4 crypts</th></tr></thead><tbody><tr><td>Control</td><td>0</td><td>0</td></tr><tr><td>AOM</td><td>12.8&#8201;&#177;&#8201;2.4</td><td>0.57&#8201;&#177;&#8201;0.20</td></tr><tr><td>AOM+AA-5HT</td><td>6.3&#8201;&#177;&#8201;1.4*</td><td>0*</td></tr><tr><td>AOM+VDM11</td><td>8.0&#8201;&#177;&#8201;1.08</td><td>0.50&#8201;&#177;&#8201;0.29</td></tr><tr><td>AOM+HU210</td><td>5.1&#8201;&#177;&#8201;1.1*</td><td>0*</td></tr></tbody></table><table-wrap-foot><p textid="33">AOM (16&#160;mg/kg in total, intraperitoneal) was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5). Animals were euthanized 6&#160;months after the first injection of AOM. Cannabinoid drugs were given every other day for the whole duration of the experiment.</p><p textid="34">*<italic>p</italic>&#8201;&lt;&#8201;0.05 vs AOM (<italic>n</italic>&#8201;=&#8201;6&#8211;9 mice for each experimental group)</p></table-wrap-foot></table-wrap>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 505 510 <span type="species:ncbi:10090">mouse</span>
###xml 704 709 <span type="species:ncbi:10090">mouse</span>
###xml 937 942 <span type="species:ncbi:10090">mouse</span>
###xml 1030 1035 <span type="species:ncbi:10090">mouse</span>
###xml 1538 1542 <span type="species:ncbi:10090">mice</span>
The total number of ACF/mouse and number of ACF/mouse with four or more crypts observed after 6 months of treatment with cannabinoid drugs in either the presence or absence of AOM treatment are shown in Table 1. AOM given alone induced the appearance of ACF in all the animals. The average number of ACF for each mouse was 12.8 +/- 2.4 (0.57 +/- 0.20 ACF with four or more crypts). The FAAH inhibitor AA-5-HT as well as the cannabinoid receptor agonist HU210 significantly reduced the total number of ACF/mouse and completely prevented the formation of ACF with four or more crypts in all animals. The anandamide reuptake inhibitor VDM11 showed a nonsignificant trend at reducing the total number of ACF/mouse and the number of ACF with four or more crypts. Table 1Effect of cannabinoid drugs (arachidonoylserotonin [AA-5-HT, 5 mg/kg], VDM11 [5 mg/kg], and HU210 [0.1 mg/kg]) on the formation of aberrant crypt foci (ACF) induced in the mouse colon by azoxymethane (AOM)Treatment (intraperitoneal)Number of ACF/mouseNumber of ACF/mouse containing >/=4 cryptsControl00AOM12.8 +/- 2.40.57 +/- 0.20AOM+AA-5HT6.3 +/- 1.4*0*AOM+VDM118.0 +/- 1.080.50 +/- 0.29AOM+HU2105.1 +/- 1.1*0*AOM (16 mg/kg in total, intraperitoneal) was administered during the first (3 mg/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at days 1 and 5). Animals were euthanized 6 months after the first injection of AOM. Cannabinoid drugs were given every other day for the whole duration of the experiment.*p < 0.05 vs AOM (n = 6-9 mice for each experimental group)
###end p 31
###begin p 32
###xml 172 177 <span type="species:ncbi:10090">mouse</span>
Effect of cannabinoid drugs (arachidonoylserotonin [AA-5-HT, 5 mg/kg], VDM11 [5 mg/kg], and HU210 [0.1 mg/kg]) on the formation of aberrant crypt foci (ACF) induced in the mouse colon by azoxymethane (AOM)
###end p 32
###begin p 33
AOM (16 mg/kg in total, intraperitoneal) was administered during the first (3 mg/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at days 1 and 5). Animals were euthanized 6 months after the first injection of AOM. Cannabinoid drugs were given every other day for the whole duration of the experiment.
###end p 33
###begin p 34
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 18 19 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
*p < 0.05 vs AOM (n = 6-9 mice for each experimental group)
###end p 34
###begin p 35
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 261 268 261 268 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 326 327 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 268 342 268 342 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Induction of aberrant crypt foci (ACF) in wild-type and CB<sub>1</sub>-deficient mice</p>
###xml 268 342 268 342 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Induction of aberrant crypt foci (ACF) in wild-type and CB<sub>1</sub>-deficient mice</p></caption>
###xml 342 353 342 353 <th xmlns:xlink="http://www.w3.org/1999/xlink">Animal type</th>
###xml 353 372 353 372 <th xmlns:xlink="http://www.w3.org/1999/xlink">Number of ACF/mouse</th>
###xml 372 414 372 412 <th xmlns:xlink="http://www.w3.org/1999/xlink">Number of ACF/mouse containing &#8805;4 crypts</th>
###xml 342 414 342 412 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Animal type</th><th>Number of ACF/mouse</th><th>Number of ACF/mouse containing &#8805;4 crypts</th></tr>
###xml 342 414 342 412 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Animal type</th><th>Number of ACF/mouse</th><th>Number of ACF/mouse containing &#8805;4 crypts</th></tr></thead>
###xml 414 428 412 426 <td xmlns:xlink="http://www.w3.org/1999/xlink">Wild-type mice</td>
###xml 428 440 426 436 <td xmlns:xlink="http://www.w3.org/1999/xlink">14.0&#8201;&#177;&#8201;0.8</td>
###xml 440 453 436 447 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.33&#8201;&#177;&#8201;0.76</td>
###xml 414 453 412 447 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Wild-type mice</td><td>14.0&#8201;&#177;&#8201;0.8</td><td>2.33&#8201;&#177;&#8201;0.76</td></tr>
###xml 455 456 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 453 464 447 458 <td xmlns:xlink="http://www.w3.org/1999/xlink">CB<sub>1</sub>-KO mice</td>
###xml 464 476 458 468 <td xmlns:xlink="http://www.w3.org/1999/xlink">16.5&#8201;&#177;&#8201;1.3</td>
###xml 476 489 468 479 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.33&#8201;&#177;&#8201;0.49</td>
###xml 453 489 447 479 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>CB<sub>1</sub>-KO mice</td><td>16.5&#8201;&#177;&#8201;1.3</td><td>2.33&#8201;&#177;&#8201;0.49</td></tr>
###xml 414 489 412 479 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Wild-type mice</td><td>14.0&#8201;&#177;&#8201;0.8</td><td>2.33&#8201;&#177;&#8201;0.76</td></tr><tr><td>CB<sub>1</sub>-KO mice</td><td>16.5&#8201;&#177;&#8201;1.3</td><td>2.33&#8201;&#177;&#8201;0.49</td></tr></tbody>
###xml 342 489 342 479 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Animal type</th><th>Number of ACF/mouse</th><th>Number of ACF/mouse containing &#8805;4 crypts</th></tr></thead><tbody><tr><td>Wild-type mice</td><td>14.0&#8201;&#177;&#8201;0.8</td><td>2.33&#8201;&#177;&#8201;0.76</td></tr><tr><td>CB<sub>1</sub>-KO mice</td><td>16.5&#8201;&#177;&#8201;1.3</td><td>2.33&#8201;&#177;&#8201;0.49</td></tr></tbody></table>
###xml 531 532 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 489 842 479 832 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">No significant differences were observed (<italic>n</italic>&#8201;=&#8201;6 for each experimental group). Animals were euthanized 6&#160;months after the first injection of AOM. ACF were induced by AOM (16&#160;mg/kg in total, intraperitoneal), which was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5)</p>
###xml 489 842 479 832 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">No significant differences were observed (<italic>n</italic>&#8201;=&#8201;6 for each experimental group). Animals were euthanized 6&#160;months after the first injection of AOM. ACF were induced by AOM (16&#160;mg/kg in total, intraperitoneal), which was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5)</p></table-wrap-foot>
###xml 261 842 261 832 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="36">Induction of aberrant crypt foci (ACF) in wild-type and CB<sub>1</sub>-deficient mice</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Animal type</th><th>Number of ACF/mouse</th><th>Number of ACF/mouse containing &#8805;4 crypts</th></tr></thead><tbody><tr><td>Wild-type mice</td><td>14.0&#8201;&#177;&#8201;0.8</td><td>2.33&#8201;&#177;&#8201;0.76</td></tr><tr><td>CB<sub>1</sub>-KO mice</td><td>16.5&#8201;&#177;&#8201;1.3</td><td>2.33&#8201;&#177;&#8201;0.49</td></tr></tbody></table><table-wrap-foot><p textid="37">No significant differences were observed (<italic>n</italic>&#8201;=&#8201;6 for each experimental group). Animals were euthanized 6&#160;months after the first injection of AOM. ACF were induced by AOM (16&#160;mg/kg in total, intraperitoneal), which was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5)</p></table-wrap-foot></table-wrap>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 142 147 <span type="species:ncbi:10090">mouse</span>
###xml 166 171 <span type="species:ncbi:10090">mouse</span>
###xml 386 391 <span type="species:ncbi:10090">mouse</span>
Table 2 shows the result of experiments performed in wild-type and CB1-deficient mice. In this series of experiments, the total number of ACF/mouse and number of ACF/mouse with four or more crypts did not change significantly between the two groups of animals. Table 2Induction of aberrant crypt foci (ACF) in wild-type and CB1-deficient miceAnimal typeNumber of ACF/mouseNumber of ACF/mouse containing >/=4 cryptsWild-type mice14.0 +/- 0.82.33 +/- 0.76CB1-KO mice16.5 +/- 1.32.33 +/- 0.49No significant differences were observed (n = 6 for each experimental group). Animals were euthanized 6 months after the first injection of AOM. ACF were induced by AOM (16 mg/kg in total, intraperitoneal), which was administered during the first (3 mg/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at days 1 and 5)
###end p 35
###begin p 36
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Induction of aberrant crypt foci (ACF) in wild-type and CB1-deficient mice
###end p 36
###begin p 37
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
No significant differences were observed (n = 6 for each experimental group). Animals were euthanized 6 months after the first injection of AOM. ACF were induced by AOM (16 mg/kg in total, intraperitoneal), which was administered during the first (3 mg/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at days 1 and 5)
###end p 37
###begin title 38
Endocannabinoid and palmitoylethanolamide content in the colon
###end title 38
###begin p 39
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 595 602 595 602 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 602 741 602 741 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Levels of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide in the mouse colon in control and in azoxymethane (AOM)-treated mice</p>
###xml 602 741 602 741 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Levels of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide in the mouse colon in control and in azoxymethane (AOM)-treated mice</p></caption>
###xml 741 750 741 750 <th xmlns:xlink="http://www.w3.org/1999/xlink">Treatment</th>
###xml 750 777 750 777 <th xmlns:xlink="http://www.w3.org/1999/xlink">anandamide (pmol/mg lipids)</th>
###xml 777 816 777 816 <th xmlns:xlink="http://www.w3.org/1999/xlink">2-arachidonoylglycerol (pmol/mg lipids)</th>
###xml 816 854 816 854 <th xmlns:xlink="http://www.w3.org/1999/xlink">palmitoylethanolamide (pmol/mg lipids)</th>
###xml 741 854 741 854 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Treatment</th><th>anandamide (pmol/mg lipids)</th><th>2-arachidonoylglycerol (pmol/mg lipids)</th><th>palmitoylethanolamide (pmol/mg lipids)</th></tr>
###xml 741 854 741 854 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Treatment</th><th>anandamide (pmol/mg lipids)</th><th>2-arachidonoylglycerol (pmol/mg lipids)</th><th>palmitoylethanolamide (pmol/mg lipids)</th></tr></thead>
###xml 854 861 854 861 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 861 872 861 870 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.9&#8201;&#177;&#8201;0.2</td>
###xml 872 886 870 882 <td xmlns:xlink="http://www.w3.org/1999/xlink">119.8&#8201;&#177;&#8201;20.1</td>
###xml 886 897 882 891 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.1&#8201;&#177;&#8201;0.5</td>
###xml 854 897 854 891 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Control</td><td>0.9&#8201;&#177;&#8201;0.2</td><td>119.8&#8201;&#177;&#8201;20.1</td><td>3.1&#8201;&#177;&#8201;0.5</td></tr>
###xml 897 900 891 894 <td xmlns:xlink="http://www.w3.org/1999/xlink">AOM</td>
###xml 900 911 894 903 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.6&#8201;&#177;&#8201;0.3</td>
###xml 911 926 903 916 <td xmlns:xlink="http://www.w3.org/1999/xlink">198.2&#8201;&#177;&#8201;29.2*</td>
###xml 926 937 916 925 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.3&#8201;&#177;&#8201;1.8</td>
###xml 897 937 891 925 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AOM</td><td>1.6&#8201;&#177;&#8201;0.3</td><td>198.2&#8201;&#177;&#8201;29.2*</td><td>6.3&#8201;&#177;&#8201;1.8</td></tr>
###xml 937 950 925 938 <td xmlns:xlink="http://www.w3.org/1999/xlink">AOM&#8201;+&#8201;AA-5-HT</td>
###xml 963 964 949 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink">,</sup>
###xml 950 967 938 953 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.4&#8201;&#177;&#8201;0.9**<sup>,</sup>***</td>
###xml 982 983 966 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">,</sup>
###xml 967 987 953 971 <td xmlns:xlink="http://www.w3.org/1999/xlink">310.9&#8201;&#177;&#8201;53.3*<sup>,</sup>****</td>
###xml 987 998 971 980 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.0&#8201;&#177;&#8201;1.4</td>
###xml 937 998 925 980 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AOM&#8201;+&#8201;AA-5-HT</td><td>3.4&#8201;&#177;&#8201;0.9**<sup>,</sup>***</td><td>310.9&#8201;&#177;&#8201;53.3*<sup>,</sup>****</td><td>5.0&#8201;&#177;&#8201;1.4</td></tr>
###xml 998 1009 980 991 <td xmlns:xlink="http://www.w3.org/1999/xlink">AOM&#8201;+&#8201;VDM11</td>
###xml 1009 1020 991 1000 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.0&#8201;&#177;&#8201;0.9</td>
###xml 1020 1034 1000 1012 <td xmlns:xlink="http://www.w3.org/1999/xlink">216.0&#8201;&#177;&#8201;80.7</td>
###xml 1034 1045 1012 1021 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.9&#8201;&#177;&#8201;2.2</td>
###xml 998 1045 980 1021 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AOM&#8201;+&#8201;VDM11</td><td>3.0&#8201;&#177;&#8201;0.9</td><td>216.0&#8201;&#177;&#8201;80.7</td><td>4.9&#8201;&#177;&#8201;2.2</td></tr>
###xml 854 1045 854 1021 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Control</td><td>0.9&#8201;&#177;&#8201;0.2</td><td>119.8&#8201;&#177;&#8201;20.1</td><td>3.1&#8201;&#177;&#8201;0.5</td></tr><tr><td>AOM</td><td>1.6&#8201;&#177;&#8201;0.3</td><td>198.2&#8201;&#177;&#8201;29.2*</td><td>6.3&#8201;&#177;&#8201;1.8</td></tr><tr><td>AOM&#8201;+&#8201;AA-5-HT</td><td>3.4&#8201;&#177;&#8201;0.9**<sup>,</sup>***</td><td>310.9&#8201;&#177;&#8201;53.3*<sup>,</sup>****</td><td>5.0&#8201;&#177;&#8201;1.4</td></tr><tr><td>AOM&#8201;+&#8201;VDM11</td><td>3.0&#8201;&#177;&#8201;0.9</td><td>216.0&#8201;&#177;&#8201;80.7</td><td>4.9&#8201;&#177;&#8201;2.2</td></tr></tbody>
###xml 741 1045 741 1021 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Treatment</th><th>anandamide (pmol/mg lipids)</th><th>2-arachidonoylglycerol (pmol/mg lipids)</th><th>palmitoylethanolamide (pmol/mg lipids)</th></tr></thead><tbody><tr><td>Control</td><td>0.9&#8201;&#177;&#8201;0.2</td><td>119.8&#8201;&#177;&#8201;20.1</td><td>3.1&#8201;&#177;&#8201;0.5</td></tr><tr><td>AOM</td><td>1.6&#8201;&#177;&#8201;0.3</td><td>198.2&#8201;&#177;&#8201;29.2*</td><td>6.3&#8201;&#177;&#8201;1.8</td></tr><tr><td>AOM&#8201;+&#8201;AA-5-HT</td><td>3.4&#8201;&#177;&#8201;0.9**<sup>,</sup>***</td><td>310.9&#8201;&#177;&#8201;53.3*<sup>,</sup>****</td><td>5.0&#8201;&#177;&#8201;1.4</td></tr><tr><td>AOM&#8201;+&#8201;VDM11</td><td>3.0&#8201;&#177;&#8201;0.9</td><td>216.0&#8201;&#177;&#8201;80.7</td><td>4.9&#8201;&#177;&#8201;2.2</td></tr></tbody></table>
###xml 1045 1557 1021 1531 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Results are expressed as mean&#8201;&#177;&#8201;SEM from four to eight animals. AOM (16&#160;mg/kg in total, intraperitoneal) was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5). In some experiments, AOM-treated mice were given the FAAH inhibitor arachidonoylserotonin (AA-5-HT) or the cellular reuptake inhibitor VDM11 (both at the dose of 5&#160;mg/kg every other day for 6&#160;months). Assay was performed 6&#160;months after the first injection of AOM.</p>
###xml 1558 1559 1532 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1573 1574 1547 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1582 1584 1556 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 1597 1598 1571 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1610 1611 1584 1585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1557 1625 1531 1599 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">*<italic>p</italic>&#8201;&lt;&#8201;0.05 and **<italic>p</italic>&#8201;&lt;&#8201;0.01 <italic>vs</italic> control; ***<italic>p</italic>&#8201;&lt;&#8201;0.05 ****<italic>p</italic>&#8201;&lt;&#8201;0.01 vs AOM</p>
###xml 1045 1625 1021 1599 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Results are expressed as mean&#8201;&#177;&#8201;SEM from four to eight animals. AOM (16&#160;mg/kg in total, intraperitoneal) was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5). In some experiments, AOM-treated mice were given the FAAH inhibitor arachidonoylserotonin (AA-5-HT) or the cellular reuptake inhibitor VDM11 (both at the dose of 5&#160;mg/kg every other day for 6&#160;months). Assay was performed 6&#160;months after the first injection of AOM.</p><p textid="42">*<italic>p</italic>&#8201;&lt;&#8201;0.05 and **<italic>p</italic>&#8201;&lt;&#8201;0.01 <italic>vs</italic> control; ***<italic>p</italic>&#8201;&lt;&#8201;0.05 ****<italic>p</italic>&#8201;&lt;&#8201;0.01 vs AOM</p></table-wrap-foot>
###xml 595 1625 595 1599 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="40">Levels of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide in the mouse colon in control and in azoxymethane (AOM)-treated mice</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Treatment</th><th>anandamide (pmol/mg lipids)</th><th>2-arachidonoylglycerol (pmol/mg lipids)</th><th>palmitoylethanolamide (pmol/mg lipids)</th></tr></thead><tbody><tr><td>Control</td><td>0.9&#8201;&#177;&#8201;0.2</td><td>119.8&#8201;&#177;&#8201;20.1</td><td>3.1&#8201;&#177;&#8201;0.5</td></tr><tr><td>AOM</td><td>1.6&#8201;&#177;&#8201;0.3</td><td>198.2&#8201;&#177;&#8201;29.2*</td><td>6.3&#8201;&#177;&#8201;1.8</td></tr><tr><td>AOM&#8201;+&#8201;AA-5-HT</td><td>3.4&#8201;&#177;&#8201;0.9**<sup>,</sup>***</td><td>310.9&#8201;&#177;&#8201;53.3*<sup>,</sup>****</td><td>5.0&#8201;&#177;&#8201;1.4</td></tr><tr><td>AOM&#8201;+&#8201;VDM11</td><td>3.0&#8201;&#177;&#8201;0.9</td><td>216.0&#8201;&#177;&#8201;80.7</td><td>4.9&#8201;&#177;&#8201;2.2</td></tr></tbody></table><table-wrap-foot><p textid="41">Results are expressed as mean&#8201;&#177;&#8201;SEM from four to eight animals. AOM (16&#160;mg/kg in total, intraperitoneal) was administered during the first (3&#160;mg/kg at days&#160;1 and 5), third (3&#160;mg/kg at days&#160;1 and 5), and at the 17th week (2&#160;mg/kg at days&#160;1 and 5). In some experiments, AOM-treated mice were given the FAAH inhibitor arachidonoylserotonin (AA-5-HT) or the cellular reuptake inhibitor VDM11 (both at the dose of 5&#160;mg/kg every other day for 6&#160;months). Assay was performed 6&#160;months after the first injection of AOM.</p><p textid="42">*<italic>p</italic>&#8201;&lt;&#8201;0.05 and **<italic>p</italic>&#8201;&lt;&#8201;0.01 <italic>vs</italic> control; ***<italic>p</italic>&#8201;&lt;&#8201;0.05 ****<italic>p</italic>&#8201;&lt;&#8201;0.01 vs AOM</p></table-wrap-foot></table-wrap>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 680 685 <span type="species:ncbi:10090">mouse</span>
###xml 1327 1331 <span type="species:ncbi:10090">mice</span>
Endocannabinoid and palmitoylethanolamide content in full-thickness colons of control and AOM-treated mice is shown in Table 3. AOM treatment significantly increased the levels of 2-AG and induced a nonsignificant trend to increase the levels of anandamide and palmitoylethanolamide. The FAAH inhibitor AA-5-HT further increased 2-AG content and significantly increased anandamide (but not palmitoylethanolamide) levels in AOM-treated mice. A nonsignificant trend to increase anandamide levels was observed also in AOM-treated mice treated with the anandamide cellular reuptake inhibitor VDM11. Table 3Levels of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide in the mouse colon in control and in azoxymethane (AOM)-treated miceTreatmentanandamide (pmol/mg lipids)2-arachidonoylglycerol (pmol/mg lipids)palmitoylethanolamide (pmol/mg lipids)Control0.9 +/- 0.2119.8 +/- 20.13.1 +/- 0.5AOM1.6 +/- 0.3198.2 +/- 29.2*6.3 +/- 1.8AOM + AA-5-HT3.4 +/- 0.9**,***310.9 +/- 53.3*,****5.0 +/- 1.4AOM + VDM113.0 +/- 0.9216.0 +/- 80.74.9 +/- 2.2Results are expressed as mean +/- SEM from four to eight animals. AOM (16 mg/kg in total, intraperitoneal) was administered during the first (3 mg/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at days 1 and 5). In some experiments, AOM-treated mice were given the FAAH inhibitor arachidonoylserotonin (AA-5-HT) or the cellular reuptake inhibitor VDM11 (both at the dose of 5 mg/kg every other day for 6 months). Assay was performed 6 months after the first injection of AOM.*p < 0.05 and **p < 0.01 vs control; ***p < 0.05 ****p < 0.01 vs AOM
###end p 39
###begin p 40
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
Levels of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide in the mouse colon in control and in azoxymethane (AOM)-treated mice
###end p 40
###begin p 41
###xml 282 286 <span type="species:ncbi:10090">mice</span>
Results are expressed as mean +/- SEM from four to eight animals. AOM (16 mg/kg in total, intraperitoneal) was administered during the first (3 mg/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at days 1 and 5). In some experiments, AOM-treated mice were given the FAAH inhibitor arachidonoylserotonin (AA-5-HT) or the cellular reuptake inhibitor VDM11 (both at the dose of 5 mg/kg every other day for 6 months). Assay was performed 6 months after the first injection of AOM.
###end p 41
###begin p 42
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 16 17 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 25 27 25 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 40 41 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
*p < 0.05 and **p < 0.01 vs control; ***p < 0.05 ****p < 0.01 vs AOM
###end p 42
###begin title 43
###xml 16 17 16 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Evaluation of CB1, CB2, FAAH, and TRPV1 mRNA levels by quantitative RT-PCR
###end title 43
###begin p 44
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 78 79 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 257 258 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 291 292 291 292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 735 737 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 739 741 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 881 882 878 879 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 889 890 886 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1051 1057 1048 1054 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1103 1104 1100 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1116 1118 1113 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CB</italic>
###xml 1118 1119 1115 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 1118 1119 1115 1116 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>1</italic></sub>
###xml 1136 1137 1133 1134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1149 1151 1146 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CB</italic>
###xml 1151 1152 1148 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1151 1152 1148 1149 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sub>
###xml 1183 1187 1180 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH</italic>
###xml 1240 1245 1237 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRPV1</italic>
###xml 1274 1277 1271 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AOM</italic>
###xml 1306 1309 1303 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ctr</italic>
###xml 1523 1544 1520 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Materials and methods</xref>
###xml 1706 1713 1703 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec11" ref-type="sec">Results</xref>
###xml 1872 1873 1869 1870 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1878 1879 1875 1876 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1889 1904 1886 1901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Double asterisk</italic>
###xml 1906 1907 1903 1904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1057 1921 1054 1918 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Relative expression analysis of cannabinoid CB<sub>1</sub> receptors (<italic>CB</italic><sub><italic>1</italic></sub>), cannabinoid CB<sub>2</sub> receptors (<italic>CB</italic><sub><italic>2</italic></sub>), fatty acid amide hydrolase (<italic>FAAH</italic>) and transient receptor potential vanilloid type 1 (<italic>TRPV1</italic>) in colons of azoxymethane (<italic>AOM</italic>)-treated mice and controls (<italic>Ctr</italic>). The assay was performed 6&#160;months after the first injection of AOM. Total RNA extracted from colons of AOM-treated mice and controls was subjected to quantitative (real-time) RT-PCR analysis as described in the &#8220;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>.&#8221; Data were analyzed by GENEX software for groupwise comparisons and statistical analysis. The lowest expression value for each target was considered as 1. See &#8220;<xref rid="Sec11" ref-type="sec">Results</xref>&#8221; for mean cycle thresholds that are indicative of absolute abundance of each target and indicate the following rank of expression in control colons: FAAH&#8201;&gt;&#8201;CB<sub>1</sub>&#8201;=&#8201;CB<sub>2</sub>&#8201;&gt;&#8201;TRPV1. <italic>Double asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.02 vs AOM</p>
###xml 1057 1921 1054 1918 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Relative expression analysis of cannabinoid CB<sub>1</sub> receptors (<italic>CB</italic><sub><italic>1</italic></sub>), cannabinoid CB<sub>2</sub> receptors (<italic>CB</italic><sub><italic>2</italic></sub>), fatty acid amide hydrolase (<italic>FAAH</italic>) and transient receptor potential vanilloid type 1 (<italic>TRPV1</italic>) in colons of azoxymethane (<italic>AOM</italic>)-treated mice and controls (<italic>Ctr</italic>). The assay was performed 6&#160;months after the first injection of AOM. Total RNA extracted from colons of AOM-treated mice and controls was subjected to quantitative (real-time) RT-PCR analysis as described in the &#8220;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>.&#8221; Data were analyzed by GENEX software for groupwise comparisons and statistical analysis. The lowest expression value for each target was considered as 1. See &#8220;<xref rid="Sec11" ref-type="sec">Results</xref>&#8221; for mean cycle thresholds that are indicative of absolute abundance of each target and indicate the following rank of expression in control colons: FAAH&#8201;&gt;&#8201;CB<sub>1</sub>&#8201;=&#8201;CB<sub>2</sub>&#8201;&gt;&#8201;TRPV1. <italic>Double asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.02 vs AOM</p></caption>
###xml 1921 1921 1918 1918 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_248_Fig1_HTML" id="MO3"/>
###xml 1051 1921 1048 1918 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="45">Relative expression analysis of cannabinoid CB<sub>1</sub> receptors (<italic>CB</italic><sub><italic>1</italic></sub>), cannabinoid CB<sub>2</sub> receptors (<italic>CB</italic><sub><italic>2</italic></sub>), fatty acid amide hydrolase (<italic>FAAH</italic>) and transient receptor potential vanilloid type 1 (<italic>TRPV1</italic>) in colons of azoxymethane (<italic>AOM</italic>)-treated mice and controls (<italic>Ctr</italic>). The assay was performed 6&#160;months after the first injection of AOM. Total RNA extracted from colons of AOM-treated mice and controls was subjected to quantitative (real-time) RT-PCR analysis as described in the &#8220;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>.&#8221; Data were analyzed by GENEX software for groupwise comparisons and statistical analysis. The lowest expression value for each target was considered as 1. See &#8220;<xref rid="Sec11" ref-type="sec">Results</xref>&#8221; for mean cycle thresholds that are indicative of absolute abundance of each target and indicate the following rank of expression in control colons: FAAH&#8201;&gt;&#8201;CB<sub>1</sub>&#8201;=&#8201;CB<sub>2</sub>&#8201;&gt;&#8201;TRPV1. <italic>Double asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.02 vs AOM</p></caption><graphic position="anchor" xlink:href="109_2007_248_Fig1_HTML" id="MO3"/></fig>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 821 825 <span type="species:ncbi:10090">mice</span>
###xml 1045 1049 <span type="species:ncbi:10090">mice</span>
###xml 1287 1291 <span type="species:ncbi:10090">mice</span>
###xml 1426 1430 <span type="species:ncbi:10090">mice</span>
The relative expression analysis, evaluated by quantitative RT-PCR, of CB1, CB2, FAAH, and TRPV1 mRNA in full-thickness colons from AOM-treated mice and controls, is depicted in Fig. 1. All targets were well detectable in the linearity range of analysis (CB1, mean cycle threshold = 26.5; CB2, mean cycle threshold = 26; FAAH, mean cycle threshold = 18; TRPV1, mean cycle threshold = 30; beta-actin, mean cycle threshold = 16.5; GADPH, mean cycle threshold = 24.5). The amplification reaction efficiencies were comparable, ranging from 96 to 108%. Colon samples showed elevated expression (relatively to the other targets and to the housekeeping genes) of FAAH, thus confirming the relevant role of this enzyme in the digestive tract [18, 19], although no variation of expression levels in colon samples from AOM-treated mice and controls was observed. Likewise, no variation of CB1 and CB2 expression levels was detected. On the contrary, a significant decrease (about fourfold) of TPRV1 expression was observed in colon samples of AOM-treated mice. Fig. 1Relative expression analysis of cannabinoid CB1 receptors (CB1), cannabinoid CB2 receptors (CB2), fatty acid amide hydrolase (FAAH) and transient receptor potential vanilloid type 1 (TRPV1) in colons of azoxymethane (AOM)-treated mice and controls (Ctr). The assay was performed 6 months after the first injection of AOM. Total RNA extracted from colons of AOM-treated mice and controls was subjected to quantitative (real-time) RT-PCR analysis as described in the "Materials and methods." Data were analyzed by GENEX software for groupwise comparisons and statistical analysis. The lowest expression value for each target was considered as 1. See "Results" for mean cycle thresholds that are indicative of absolute abundance of each target and indicate the following rank of expression in control colons: FAAH > CB1 = CB2 > TRPV1. Double asterisk, p < 0.02 vs AOM
###end p 44
###begin p 45
###xml 46 47 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 59 61 59 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CB</italic>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 61 62 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>1</italic></sub>
###xml 79 80 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 92 94 92 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CB</italic>
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 94 95 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sub>
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH</italic>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRPV1</italic>
###xml 217 220 217 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AOM</italic>
###xml 249 252 249 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ctr</italic>
###xml 466 487 466 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Materials and methods</xref>
###xml 649 656 649 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec11" ref-type="sec">Results</xref>
###xml 815 816 815 816 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 821 822 821 822 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 832 847 832 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Double asterisk</italic>
###xml 849 850 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
Relative expression analysis of cannabinoid CB1 receptors (CB1), cannabinoid CB2 receptors (CB2), fatty acid amide hydrolase (FAAH) and transient receptor potential vanilloid type 1 (TRPV1) in colons of azoxymethane (AOM)-treated mice and controls (Ctr). The assay was performed 6 months after the first injection of AOM. Total RNA extracted from colons of AOM-treated mice and controls was subjected to quantitative (real-time) RT-PCR analysis as described in the "Materials and methods." Data were analyzed by GENEX software for groupwise comparisons and statistical analysis. The lowest expression value for each target was considered as 1. See "Results" for mean cycle thresholds that are indicative of absolute abundance of each target and indicate the following rank of expression in control colons: FAAH > CB1 = CB2 > TRPV1. Double asterisk, p < 0.02 vs AOM
###end p 45
###begin title 46
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Expression of activated caspase-3 and caspase-9 on colon of AOM-treated mice
###end title 46
###begin p 47
###xml 19 20 19 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 401 407 401 407 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 459 466 459 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA-5-HT</italic>
###xml 490 491 490 491 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 516 517 516 517 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 574 577 574 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AOM</italic>
###xml 647 648 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 823 824 819 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 931 942 925 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Number sign</italic>
###xml 944 945 938 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 966 981 960 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">triple asterisk</italic>
###xml 983 984 977 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 407 999 407 993 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Effect of the FAAH inhibitor arachidonoylserotonin (<italic>AA-5-HT</italic>) on cleaved caspase-3 (<bold>a</bold>) and cleaved caspase-9 (<bold>b</bold>) expression in colon of mice treated with azoxymethane (<italic>AOM</italic>). The assay was performed 6&#160;months after the first injection of AOM. <italic>A</italic> Relative expression of cleaved caspases-3 (active fragment p17) and caspase-9 (active fragment p34) was quantified by densitometric scanning and normalized by &#945;-tubulin. <italic>B</italic> Representative Western blot analysis. Data are expressed as mean&#8201;&#177;&#8201;SE of three independent experiments. <italic>Number sign</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 vs control; <italic>triple asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 vs AOM</p>
###xml 407 999 407 993 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Effect of the FAAH inhibitor arachidonoylserotonin (<italic>AA-5-HT</italic>) on cleaved caspase-3 (<bold>a</bold>) and cleaved caspase-9 (<bold>b</bold>) expression in colon of mice treated with azoxymethane (<italic>AOM</italic>). The assay was performed 6&#160;months after the first injection of AOM. <italic>A</italic> Relative expression of cleaved caspases-3 (active fragment p17) and caspase-9 (active fragment p34) was quantified by densitometric scanning and normalized by &#945;-tubulin. <italic>B</italic> Representative Western blot analysis. Data are expressed as mean&#8201;&#177;&#8201;SE of three independent experiments. <italic>Number sign</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 vs control; <italic>triple asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 vs AOM</p></caption>
###xml 999 999 993 993 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_248_Fig2_HTML" id="MO4"/>
###xml 401 999 401 993 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="48">Effect of the FAAH inhibitor arachidonoylserotonin (<italic>AA-5-HT</italic>) on cleaved caspase-3 (<bold>a</bold>) and cleaved caspase-9 (<bold>b</bold>) expression in colon of mice treated with azoxymethane (<italic>AOM</italic>). The assay was performed 6&#160;months after the first injection of AOM. <italic>A</italic> Relative expression of cleaved caspases-3 (active fragment p17) and caspase-9 (active fragment p34) was quantified by densitometric scanning and normalized by &#945;-tubulin. <italic>B</italic> Representative Western blot analysis. Data are expressed as mean&#8201;&#177;&#8201;SE of three independent experiments. <italic>Number sign</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 vs control; <italic>triple asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 vs AOM</p></caption><graphic position="anchor" xlink:href="109_2007_248_Fig2_HTML" id="MO4"/></fig>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
AOM significantly (p < 0.001) reduced the cleavage of the p34 precursor of caspases-3 into its p17 active fragment and the p46 precursor of caspases-9 into its p34 active fragment in full-thickness colons (Fig. 2a and b). Treatment with AA-5-HT significantly reduced the effect of AOM on the expression of the activated caspase-3 but not on the expression of the activated caspases-9 (Fig. 2a and b). Fig. 2Effect of the FAAH inhibitor arachidonoylserotonin (AA-5-HT) on cleaved caspase-3 (a) and cleaved caspase-9 (b) expression in colon of mice treated with azoxymethane (AOM). The assay was performed 6 months after the first injection of AOM. A Relative expression of cleaved caspases-3 (active fragment p17) and caspase-9 (active fragment p34) was quantified by densitometric scanning and normalized by alpha-tubulin. B Representative Western blot analysis. Data are expressed as mean +/- SE of three independent experiments. Number sign, p < 0.001 vs control; triple asterisk, p < 0.001 vs AOM
###end p 47
###begin p 48
###xml 52 59 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA-5-HT</italic>
###xml 83 84 83 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 167 170 167 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AOM</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 416 417 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 524 535 518 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Number sign</italic>
###xml 537 538 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 559 574 553 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">triple asterisk</italic>
###xml 576 577 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
Effect of the FAAH inhibitor arachidonoylserotonin (AA-5-HT) on cleaved caspase-3 (a) and cleaved caspase-9 (b) expression in colon of mice treated with azoxymethane (AOM). The assay was performed 6 months after the first injection of AOM. A Relative expression of cleaved caspases-3 (active fragment p17) and caspase-9 (active fragment p34) was quantified by densitometric scanning and normalized by alpha-tubulin. B Representative Western blot analysis. Data are expressed as mean +/- SE of three independent experiments. Number sign, p < 0.001 vs control; triple asterisk, p < 0.001 vs AOM
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 252 255 252 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 710 711 710 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 712 713 712 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 212 217 <span type="species:ncbi:9606">human</span>
###xml 611 617 <span type="species:ncbi:9606">humans</span>
ACF are believed to be the earliest identifiable neoplastic lesions in the colon carcinogenetic model [1-3, 20]. They exhibit a number of molecular mutations in regulatory genes consonant with the development of human colon cancer, most notably in the ras oncogene and antigen-presenting cell tumor suppressor gene [20]. In comparison to normal crypts, ACF have greater size, larger and often elongated openings, thicker lining of epithelial cells, compression of adjacent crypts, and are more darkly stained with methylene blue [1-3, 20]. Recent studies also suggest that ACF are precursors of colon cancer in humans, and this further stimulates the need to identify drugs that may prevent their progression [1-3, 20]. Our findings indicate that the blockade of endocannabinoid enzymatic degradation protects against ACF formation.
###end p 50
###begin p 51
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 269 270 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1238 1239 1238 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1240 1241 1240 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1243 1245 1243 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1642 1644 1642 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1730 1732 1730 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1824 1826 1824 1826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 2031 2032 2031 2032 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2056 2058 2056 2058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 2155 2157 2155 2157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 2646 2648 2646 2648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 2790 2793 2790 2793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 2849 2851 2849 2851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 3026 3027 3026 3027 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 3093 3094 3093 3094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 115 119 <span type="species:ncbi:10090">Mice</span>
###xml 927 932 <span type="species:ncbi:10090">mouse</span>
###xml 1500 1504 <span type="species:ncbi:10090">mice</span>
###xml 1593 1597 <span type="species:ncbi:10090">mice</span>
###xml 1678 1682 <span type="species:ncbi:10090">mice</span>
###xml 2448 2451 <span type="species:ncbi:10116">rat</span>
###xml 2468 2473 <span type="species:ncbi:10090">mouse</span>
###xml 2806 2809 <span type="species:ncbi:10116">rat</span>
###xml 2835 2839 <span type="species:ncbi:10090">mice</span>
###xml 2959 2964 <span type="species:ncbi:9606">human</span>
FAAH is a membrane-associated protein responsible of the degradation of endocannabinoids anandamide and 2-AG [21]. Mice lacking FAAH are severely impaired in their ability to degrade anandamide and, when treated with this endocannabinoid, exhibit an array of intense CB1-dependent behavioral responses, including hypomotility, analgesia, catalepsy, and hypothermia [22]. In the digestive tract, FAAH inhibition results in reduction in intestinal motility [23] and anti-inflammatory effects in vivo [12, 24]. Furthermore, FAAH knockout results in lower sensitivity to the proinflammatory agent dinitrobenzene sulfonic acid (DNBS) [12]. The anti-inflammatory role of FAAH is relevant in the light of the observation that inflammation plays an important role in colon carcinogenesis [25]. In this paper, we have shown that a 6-month treatment with AA-5-HT, a selective FAAH inhibitor, strongly reduces the formation of ACF in the mouse colon and completely prevented the number of ACF with crypt multiplicity of greater than or equal to 4. The significant reduction in the number of ACF with four or more crypts is relevant in the light of previous reports in which larger crypts were found to be best correlated with final tumor incidence [1-3, 20]. We believe that the effect of AA-5-HT is due to FAAH inhibition and not to nonspecific effects or interactions with cannabinoid receptors for the following reasons: (1) AA-5-HT administration increased the levels of anandamide and 2-AG in the colon of mice treated with AOM, similar to that previously observed in the small intestine of healthy mice after acute intraperitoneal administration [23] or in the colon or DNBS-treated mice after repeated intraperitoneal administration [24] with this compound; (2) AA-5-HT displays little or no affinity for cannabinoid receptors [16]; (3) AA-5-HT exerted protective effects in the present study at a dose (5 mg/kg) previously shown to be inactive in the "open field," "hot plate," and rectal hypothermia tests, which are predictive of CB1 activation in rodents [16]; (4) AA-5-HT was also previously found to be ineffective against anandamide cellular reuptake [16], a mechanism that, however, does not seem to be involved in the control of ACF formation, as VDM11, a selective inhibitor of anandamide cellular uptake, did not significantly affect ACF formation in the present study. The dose of VDM11 used in the present experiments was found to enhance rat hippocampal and mouse brain endocannabinoid levels and to exert neuroprotective effects when administered (intraperitoneally) subchronically every other day (as in our experimental conditions) [26]. Consistent with our results, it was previously shown that chronic administration of AA-5-HT (injected intratumor) inhibits the growth of K-ras-transformed rat thyroid cells in athymic mice in vivo [26]. More relevant to our present findings, AA-5-HT was also previously shown to inhibit the proliferation of human colorectal carcinoma cells in vitro in a way attenuated by CB1 receptor blockade, while increasing cell endocannabinoid levels [7]. However, in these two previous studies and unlike our present findings, VDM11 was also found to exert antitumor effects both in vivo (albeit injected intratumor) and in vitro.
###end p 51
###begin p 52
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 487 488 487 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 561 562 561 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 569 570 569 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 819 820 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1224 1225 1224 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1737 1738 1737 1738 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1807 1809 1807 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1811 1813 1811 1813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1898 1899 1898 1899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1954 1955 1954 1955 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2096 2097 2096 2097 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2400 2401 2400 2401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2409 2410 2409 2410 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2484 2485 2484 2485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 2486 2487 2486 2487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 2489 2491 2489 2491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 2492 2494 2492 2494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 2555 2557 2555 2557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 2743 2745 2743 2745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 2791 2793 2791 2793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 3192 3194 3192 3194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 3334 3335 3334 3335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 3337 3338 3337 3338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 657 662 <span type="species:ncbi:9606">human</span>
###xml 1859 1864 <span type="species:ncbi:9606">human</span>
###xml 2122 2126 <span type="species:ncbi:10090">mice</span>
###xml 2383 2387 <span type="species:ncbi:10090">mice</span>
###xml 2649 2653 <span type="species:ncbi:10116">rats</span>
###xml 2785 2789 <span type="species:ncbi:10116">rats</span>
###xml 2935 2938 <span type="species:ncbi:10116">rat</span>
The formation of ACF in mice after treatment with AOM was associated per se to an increase in intestinal 2-AG levels, with a trend toward the increase in anandamide levels too. It should be noted that we performed endocannabinoid assay on full-thickness segments, and thus the cell type responsible of 2-AG overproduction is presently unknown. However, it is likely that these variations reflects changes occurring in mucosal cells, as ACF are located on the mucosa of the intestine [2, 3]. No changes were observed, instead, in the expression of cannabinoid CB1 and CB2 receptors, as assessed by quantitative real-time PCR. This finding is consistent with human studies, which showed increased levels of endocannabinoids but not of cannabinoid receptors, in the mucosa of colorectal adenomatous polyps and carcinomas [7]. It is likely that the enhanced 2-AG levels in the gut exert protective effects on colon carcinogenesis for the following reasons: (1) Pharmacological blockade of endocannabinoid degradation and subsequent elevation of both 2-AG and anandamide levels results in a reduction in preneoplastic lesions (see above); (2) anandamide and 2-AG potently inhibit the proliferation of colorectal carcinoma cells [7]; (3) the protective effect of AA-5-HT on ACF formation observed here was mimicked by the synthetic cannabinoid receptor agonist HU210; we used HU210 rather than endocannabinoids because of its pharmacokinetic properties (i.e., longer half-life of HU210 as opposed to the high metabolic instability of both anandamide and 2-AG). On these bases, we speculate that the administration of AOM in animals increases 2-AG levels, which, in turn, exerts protective effects. A likely target of 2-AG is the cannabinoid CB2 receptor, whose stimulation is known to exert proapoptotic effects [27, 28] and to mediate antiproliferative effects on human colorectal carcinoma cell lines [7]. It is unlikely that 2-AG could act on cannabinoid CB1 receptors to mediate protective effects because in the present study we have observed no statistical differences in ACF formation between CB1-deficient and wild-type mice. Others have found that systemic or local treatment with cannabinoids inhibited the growth of various types of tumor or tumor cell xenografts in vivo, including lung carcinoma, glioma, thyroid epithelioma, lymphoma, breast carcinoma, and skin carcinoma in mice, via both CB1- and CB2-mediated pathways as well as through noncannabinoid receptor mechanisms [4-6, 29-30], including cyclooxygenase-2 in colorectal carcinoma cells [31]. It is interesting to note that a recent study showed that chronic oral administration to rats of the antiobesity drug orlistat, which is a very potent inhibitor of 2-AG biosynthesis [32], causes increased formation of ACF in rats [33]. This finding might be interpreted in the light of our present results, by hypothesizing that orlistat, by inhibiting 2-AG formation in the rat colon, might counteract the protection against ACF formation exerted by this endocannabinoid. We did not test the involvement of TRPV1 receptors, which have been proposed as an alternative target for anandamide in the gut under pathological conditions [34], because we found a significant increase only in the levels of 2-AG, which, in contrast to anandamide, does not activate TRPV1 receptors [5, 6].
###end p 52
###begin p 53
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 1056 1058 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 1965 1966 1965 1966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1967 1968 1967 1968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1970 1972 1970 1972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
Caspases, a group of cysteine proteases, play an essential role in programmed cell death [35, 36]. They convey the apoptotic signal in a proteolytic cascade, by cleaving and activating other enzymes that subsequently degrade cellular targets that lead to cell death. The initiator caspases include caspase-8 and caspase-9 [35, 36]. Caspase-8 is activated in response to receptors with a death domain that interacts with the fas-associated death domain (extrinsic pathway), whereas the activation of caspase-9 is a consequence of cytochrome c and apoptosis-activating factor 1 interaction with AP-1 (intrinsic pathway) [35, 36]. Both initiators lead to the activation of the final effector caspase-3, which cleaves and inactivates several vital cellular proteins (e.g., DNA repair enzymes) involved in cancer cell life [35, 36]. It has been experimentally demonstrated that during colorectal cancer formation, there is an increased cell proliferation correlated with a reduction in apoposis [37]. In agreement with a reduction in apoptosis in colon cancer [38], we have shown here that AOM treatment reduces the expression of the activated caspase-3 and caspase-9 in full-thickness colons. More importantly, treatment with the FAAH inhibitor AA-5-HT partially reversed the AOM effect on caspase-3, suggesting that the activation of this caspase isoform is involved in AA-5-HT-induced inhibition of ACF formation. Therefore, our data allow us to suggest that whatever their exact molecular target(s), pharmacologically elevated endocannabinoids reduce ACF formation via proapoptotic effects. It is very likely that the intrinsic pathway is not involved in these effects, as AA-5-HT did not affect the reduction in expression of activated caspase-9 observed in the colon of AOM-treated animals. In other experimental studies, it has been observed that cannabinoids induce apoptosis in other types of cancer with involvement of extrinsic or intrinsic pathways or both [4-6, 29].
###end p 53
###begin p 54
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 671 672 671 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 260 266 <span type="species:ncbi:9606">humans</span>
###xml 816 821 <span type="species:ncbi:9606">human</span>
In summary, the present study provides strong evidence that enhancement of colon endocannabinoid levels through pharmacological inhibition of their enzymatic hydrolysis may be protective against preneoplastic lesions in the mouse colon; a condition that, like humans adenomatous polyps and colorectal carcinoma [7], is accompanied by an elevated endocannabinoid tone. This protective effect could be due to indirect activation of one or more of the several targets proposed to date for the endocannabinoids and appears to involve caspase-3 activation and subsequent apoptosis of colon preneoplastic cells. Further studies will be required to investigate if cannabinoid CB2 receptors are involved in the protective effects of AA-5-HT and HU210 and if these effects have any therapeutic relevance for the treatment of human colon carcinoma.
###end p 54
###begin p 55
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prin</italic>
This work was supported by Prin, Enrico and Enrica Sovena Foundation, Regione Campania, Epitech, S.r.l. (to SP and VDM).
###end p 55
###begin p 56
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Competing interests</bold>
Competing interests The Authors declare no competing interests.
###end p 56
###begin title 57
References
###end title 57
###begin article-title 58
Genetic testing for colon cancer
###end article-title 58
###begin article-title 59
Aberrant crypt foci of the colon as precursors of adenoma and cancer
###end article-title 59
###begin article-title 60
Aberrant crypt foci
###end article-title 60
###begin article-title 61
Cannabinoids and cancer: pros and cons of an antitumour strategy
###end article-title 61
###begin article-title 62
The endocannabinoid system and its therapeutic exploitation
###end article-title 62
###begin article-title 63
The endocannabinoid system as an emerging target of pharmacotherapy
###end article-title 63
###begin article-title 64
Possible endocannabinoid control of colorectal cancer growth
###end article-title 64
###begin article-title 65
Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes
###end article-title 65
###begin article-title 66
###xml 72 76 <span type="species:ncbi:10116">rats</span>
Effect of olive oil on early and late events of colon carcinogenesis in rats: modulation of arachidonic acid metabolism and local prostaglandin E(2)synthesis
###end article-title 66
###begin article-title 67
The endogenous cannabinoid system controls extinction of aversive memories
###end article-title 67
###begin article-title 68
###xml 110 114 <span type="species:ncbi:10116">rats</span>
The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats
###end article-title 68
###begin article-title 69
The endogenous cannabinoid system protects against colonic inflammation
###end article-title 69
###begin article-title 70
Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels
###end article-title 70
###begin article-title 71
###xml 100 104 <span type="species:ncbi:10116">rats</span>
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats
###end article-title 71
###begin article-title 72
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
###end article-title 72
###begin article-title 73
Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase
###end article-title 73
###begin article-title 74
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity
###end article-title 74
###begin article-title 75
The gastrointestinal pharmacology of cannabinoids: an update
###end article-title 75
###begin article-title 76
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract
###end article-title 76
###begin article-title 77
Aberrant crypt foci as microscopic precursors of colorectal cancer
###end article-title 77
###begin article-title 78
Modulators of endocannabinoid enzymic hydrolysis and membrane transport
###end article-title 78
###begin article-title 79
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
###end article-title 79
###begin article-title 80
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Fatty acid amide hydrolase controls mouse intestinal motility in vivo
###end article-title 80
###begin article-title 81
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation
###end article-title 81
###begin article-title 82
Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation
###end article-title 82
###begin article-title 83
A new strategy to block tumor growth by inhibiting endocannabinoid inactivation
###end article-title 83
###begin article-title 84
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor
###end article-title 84
###begin article-title 85
CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents
###end article-title 85
###begin article-title 86
Effects on cell viability
###end article-title 86
###begin article-title 87
Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids
###end article-title 87
###begin article-title 88
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2
###end article-title 88
###begin article-title 89
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis
###end article-title 89
###begin article-title 90
###xml 94 98 <span type="species:ncbi:10116">rats</span>
The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen
###end article-title 90
###begin article-title 91
Endocannabinoid overactivity and intestinal inflammation
###end article-title 91
###begin article-title 92
Recent advances in understanding the cell death pathways activated by anticancer therapy
###end article-title 92
###begin article-title 93
Caspase inhibitors promote alternative cell death pathways
###end article-title 93
###begin article-title 94
Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC
###end article-title 94
###begin article-title 95
Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents
###end article-title 95
###begin title 96
Abbreviations
###end title 96
###begin p 97
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-</italic>
N-arachidonoylserotonin,
###end p 97
###begin p 98
aberrant crypt foci,
###end p 98
###begin p 99
arachidonylethanolamide,
###end p 99
###begin p 100
azoxymethane,
###end p 100
###begin p 101
2-arachidonylglycerol,
###end p 101
###begin p 102
dimethylsulfoxide;
###end p 102
###begin p 103
fatty acid amide hydrolase,
###end p 103
###begin p 104
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
[(6aR)-trans-3-(1,1--dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d] pyran-9-methanol], 
###end p 104
###begin p 105
reverse transcription polymerase chain reaction,
###end p 105
###begin p 106
transient receptor potential vanilloid type 1
###end p 106
###begin p 107
Angelo A. Izzo and Gabriella Aviello equally contributed to this work.
###end p 107
###begin p 108
Angelo A. Izzo, Gabriella Aviello, Stefania Petrosino, Pierangelo Orlando, Francesca Borrelli, Raffaele Capasso, Francesco Capasso, and Vincenzo Di Marzo are part of the Endocannabinoid Research Group.
###end p 108

